Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models

13 Jan 2023

Abstract excerpt

Immunotherapy of metastatic melanoma (MM) has vastly improved the longevity of only a minority of patients. To broaden the repertoire of agents against MM, we investigated the effectiveness of locally interrupting tumor blood endothelial cell proliferation and angiogenesis, arginine deprivation, or both on the growth of melanoma by constructing and characterizing the effectiveness of four oncolytic adenoviruses....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to CAR-T cell therapy research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36816748
DOI: 10.1016/j.omto.2023.01.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse modelsPMID 36816748Read ↗

Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1Semantic proximity Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaSemantic proximity Read ↗

Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.Semantic proximity Read ↗

Generation of Orthotopic Patient-Derived Xenograft in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for MelanomaSemantic proximity Read ↗

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.Semantic proximity Read ↗

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.Semantic proximity Read ↗

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for MelanomaSemantic proximity Read ↗

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in HumansSemantic proximity Read ↗

Localized Delivery of an IL-2–Expressing Oncolytic Vaccinia Virus Enhances PD-1 Pathway Inhibition in a De-Novo Esophageal Adenocarcinoma ModelSemantic proximity Read ↗

Telomere‐based DNA damage responses: a new approach to melanomaSemantic proximity Read ↗

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.